BG103740A - Фитостеролен състав за предпазване от болестта наалцхаймер - Google Patents

Фитостеролен състав за предпазване от болестта наалцхаймер

Info

Publication number
BG103740A
BG103740A BG103740A BG10374099A BG103740A BG 103740 A BG103740 A BG 103740A BG 103740 A BG103740 A BG 103740A BG 10374099 A BG10374099 A BG 10374099A BG 103740 A BG103740 A BG 103740A
Authority
BG
Bulgaria
Prior art keywords
composition
phytostyrene
alzheimer
disease
prevention
Prior art date
Application number
BG103740A
Other languages
English (en)
Inventor
Egon Novak
Original Assignee
Forbes Medi-Tech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi-Tech Inc. filed Critical Forbes Medi-Tech Inc.
Publication of BG103740A publication Critical patent/BG103740A/bg

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретението се отнася до метод за предпазване и/или забавяне началото на болестта на Алцхаймер при животни чрез прилагане на фитостеролен състав, както и до композиция, включваща фитостеролен състав със същото приложение.
BG103740A 1997-12-18 1999-09-17 Фитостеролен състав за предпазване от болестта наалцхаймер BG103740A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/993,901 US5985936A (en) 1997-12-18 1997-12-18 Method of preventing and delaying onset of Alzheimer's disease and composition therefor
PCT/CA1998/001147 WO1999032097A2 (en) 1997-12-18 1998-12-18 Phytosterol composition for preventing alzheimer's disease

Publications (1)

Publication Number Publication Date
BG103740A true BG103740A (bg) 2000-05-31

Family

ID=25540052

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103740A BG103740A (bg) 1997-12-18 1999-09-17 Фитостеролен състав за предпазване от болестта наалцхаймер

Country Status (18)

Country Link
US (1) US5985936A (bg)
EP (1) EP0967982A2 (bg)
CN (1) CN1252724A (bg)
AU (1) AU1656099A (bg)
BG (1) BG103740A (bg)
BR (1) BR9807577A (bg)
CA (1) CA2281710A1 (bg)
EE (1) EE9900354A (bg)
GE (1) GEP20022783B (bg)
HU (1) HUP0100737A3 (bg)
LT (1) LT4801B (bg)
LV (1) LV12438B (bg)
MD (1) MD1920F2 (bg)
NO (1) NO993979L (bg)
PL (1) PL335421A1 (bg)
RU (1) RU2173151C2 (bg)
SK (1) SK112999A3 (bg)
WO (1) WO1999032097A2 (bg)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
EP1225880A2 (en) * 1999-11-04 2002-07-31 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
US6610320B2 (en) 2000-04-14 2003-08-26 Mars, Incorporated Compositions and methods for improving vascular health
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
WO2002064735A2 (en) * 2001-02-12 2002-08-22 Akzo Nobel N.V. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7192944B2 (en) * 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
AU2005208566A1 (en) * 2004-01-22 2005-08-11 Genaissance Pharmaceuticals, Inc. APOE genetic markers associated with age of onset of Alzheimer's Disease
AU2005319578A1 (en) * 2004-11-24 2006-06-29 Neopro Labs, Llc Methods and compositions for treating conditions
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
WO2009118187A1 (en) * 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
WO2010104375A1 (en) * 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US9011937B2 (en) * 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
WO2012149111A1 (en) 2011-04-26 2012-11-01 The Regents Of The University Of California Methods of promoting cns neuronal repair by inhibiting lrp-1
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123618A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for increasing bcl2 gene expression
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
KR20200083969A (ko) 2017-09-14 2020-07-09 피닉스 바이오테크놀러지 인코포레이티드. 신경학적 상태를 치료하기 위한 방법 및 개선된 신경보호 조성물
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
EP3842039A1 (en) * 2019-12-24 2021-06-30 Folium Biosciences Europe B.V. Food supplement comprising cannbinoids and phytosterols for alzheimer
WO2021130002A1 (en) 2019-12-24 2021-07-01 Folium Biosciences Europe B.V. Food supplement for alzheimer
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
WO1994018994A1 (en) * 1993-02-23 1994-09-01 Pharmakon Usa, Inc. Therapeutic herbal composition
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
DK1707572T3 (da) * 1994-09-29 2014-05-12 Univ British Columbia Sterolsammensætninger fra papirmassesæbe
CN1179903A (zh) * 1996-10-09 1998-04-29 李辉 营养丝米粉
ES2285772T3 (es) * 1997-05-15 2007-11-16 University Of Washington Composicion y metodos para tratar la enfermedad de alzheimer y otras amiloidosis.

Also Published As

Publication number Publication date
NO993979D0 (no) 1999-08-18
SK112999A3 (en) 2001-11-06
LT99114A (lt) 2001-01-25
MD1920F2 (ro) 2002-05-31
EE9900354A (et) 2000-02-15
MD990262A (en) 2000-06-30
WO1999032097A3 (en) 1999-09-02
HUP0100737A2 (hu) 2001-09-28
BR9807577A (pt) 2001-08-07
US5985936A (en) 1999-11-16
RU2173151C2 (ru) 2001-09-10
LV12438B (en) 2000-09-20
CA2281710A1 (en) 1999-07-01
LT4801B (lt) 2001-06-25
HUP0100737A3 (en) 2002-07-29
PL335421A1 (en) 2000-04-25
WO1999032097A2 (en) 1999-07-01
LV12438A (en) 2000-03-20
AU1656099A (en) 1999-07-12
CN1252724A (zh) 2000-05-10
NO993979L (no) 1999-10-13
GEP20022783B (en) 2002-09-25
EP0967982A2 (en) 2000-01-05

Similar Documents

Publication Publication Date Title
BG103740A (bg) Фитостеролен състав за предпазване от болестта наалцхаймер
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BG104315A (bg) Простагландинови агонисти и тяхното използване за лечение на заболявания на костите
MD1745B2 (en) 4,5-dimethyl-N-2-propenyl-2-(trimethylsilyl)-3-thiophencarboxamide, fungicidal composition on base thereof and method of plants diseases control
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
MY132529A (en) Paroxetine hydrochloride anhydrate
BG101132A (bg) Пиридоанилирани тиенилови и фуранилови оксазолидинони
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
UA34428C2 (uk) Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки
OA09772A (en) "mometasone furoate monohydrate, process for making same and pharmaceutical compositions".
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
PL309282A1 (en) Application of 2-amino-6-n-propyl-amino- 4,5,6,7-tetrahydrobenzothiasole (pramipexol) as an antidepressant
IL116746A0 (en) Use of 3, 4-diphenyl chromans for the preparation of pharmaceutical compositions
BG105197A (bg) Полиморфна форма на лекарствено средство
BG102589A (bg) 3-азетидинилалкилпиперидини или - пиролидини катотахикининови антагонисти
BG104179A (bg) Използване на фанхинон за лечението на болестта на алцхаймер
BG102660A (bg) Комбиниран фармацевтичен препарат от lнrн - аналози и антиестрогени за лечение на гинекологични смущения
BG105275A (bg) Производни на tan-1057
CA2132544A1 (en) Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.